COVID-19: What type of cytokine storm are we dealing with?
- 1 January 2021
- journal article
- letter
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (1), 197-198
- https://doi.org/10.1002/jmv.26317
Abstract
We read with great interest the comment published by Andrianopoulos et al. in which the authors advocate for cautious use of tocilizumab in COVID‐19 patients 1. Tocilizumab is a monoclonal antibody against the interleukin‐6 receptor which has immunosuppressive properties. Whereas accumulating results from uncontrolled trials present tocilizumab as an effective agent blocker of disease progression, some contrasting studies also progressively appear in COVID‐19 literature 2‐5. This muddies the waters and makes the situation more confused.This publication has 12 references indexed in Scilit:
- Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine stormJournal of Medical Virology, 2021
- Elevated interleukin‐6 and severe COVID‐19: A meta‐analysisJournal of Medical Virology, 2020
- Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, ItalyEuropean Journal of Internal Medicine, 2020
- Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of careJournal of Clinical Virology, 2020
- Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)Microorganisms, 2020
- Use of Tocilizumab for COVID-19-Induced Cytokine Release SyndromeSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2020
- Disease–Drug Interactions in Inflammatory States via Effects on CYP‐Mediated Drug ClearanceThe Journal of Clinical Pharmacology, 2018
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels*Critical Care Medicine, 2004
- Such stuff as dreams are made on: mediator-directed therapy in sepsisNature Reviews Drug Discovery, 2003